Announcement of an Exempt Purchase

Laboratory Supplies and Reagents for the GeneAssure Solid Tumor Next-Generation Sequencing (NGS) assay. This comprehensive assay is used for detection of gene mutation in the tumor Deoxyribonucleic Acid (DNA), translocations or fusions in the tumor Ribonucleic Acid (RNA), and other biomarkers such as tumor mutation burden and microsatellite instability status.

This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical services necessary for the delivery of care and treatment at medical, dental, or veterinary teaching facilities utilized by SIU or U of I (30 ILCS 500 / 1-13(b-5)) Without these supplies and reagents, we will not be able to provide patient testing. This will result in patients seeking care elsewhere leading to a loss in revenue.